Loncastuximab tesirine

Generic Name
Loncastuximab tesirine
Brand Names
Zynlonta
Drug Type
Biotech
Chemical Formula
-
CAS Number
1879918-31-6
Unique Ingredient Identifier
7K5O7P6QIU
Background

Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. Prognosis is poor and more effective therapies are needed to treat relapsed/refractory cases and improve survival. On April 23 2021, the Food and Drug Administration granted accelerated...

Indication

Loncastuximab tesirine is indicated for the treatment of adults with relapsed or refractory large B-cell lymphoma who have undergone two or more prior lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. The above indication is approved under...

Associated Conditions
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory High Grade B-cell Lymphoma (HGBCL), Relapsed Diffuse large B-cell lymphoma NOS, Relapsed High Grade B-cell Lymphoma (HGBCL)
Associated Therapies
-
Clinical Trials
Related News

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

First Posted Date
2023-08-14
Last Posted Date
2024-11-08
Lead Sponsor
University of Birmingham
Target Recruit Count
210
Registration Number
NCT05991388
Locations
🇬🇧

Bristol Royal Hospital for Children, Bristol, United Kingdom

🇬🇧

Royal Manchester Children's Hospital, Manchester, United Kingdom

🇬🇧

Birmingham Children's Hospital, Birmingham, United Kingdom

A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

First Posted Date
2022-12-21
Last Posted Date
2024-06-21
Lead Sponsor
ADC Therapeutics S.A.
Target Recruit Count
56
Registration Number
NCT05660395
Locations
🇧🇷

Hospital Sírio-Libanês - Brasília, Brasília, Brazil

🇧🇷

Hospital Sírio-Libanês - São Paulo, São Paulo, Brazil

🇰🇷

Kyungpook National University Chilgok Hospital, Daegu, Daegu Gwang'yeogsi, Korea, Republic of

and more 11 locations

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

Phase 2
Recruiting
Conditions
Lymphoma
Large B-cell Lymphoma
Interventions
Drug: Loncastuximab Tesirine
First Posted Date
2022-07-19
Last Posted Date
2024-12-18
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT05464719
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

First Posted Date
2022-07-12
Last Posted Date
2024-10-17
Lead Sponsor
University of Washington
Target Recruit Count
40
Registration Number
NCT05453396
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant

First Posted Date
2022-02-03
Last Posted Date
2023-11-01
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Registration Number
NCT05222438
Locations
🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Loncastuximab Tesirine in WM

First Posted Date
2022-01-13
Last Posted Date
2024-03-22
Lead Sponsor
Shayna Sarosiek, MD
Target Recruit Count
36
Registration Number
NCT05190705
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)

First Posted Date
2021-12-03
Last Posted Date
2024-01-31
Lead Sponsor
ADC Therapeutics S.A.
Target Recruit Count
41
Registration Number
NCT05144009
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

🇵🇷

Hospital Español Auxilio Mutuo, San Juan, Puerto Rico

🇺🇸

New York Cancer & Blood Specialists - New Hyde Park, Babylon, New York, United States

and more 38 locations

Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

First Posted Date
2021-09-22
Last Posted Date
2024-07-23
Lead Sponsor
Brian Hill
Target Recruit Count
36
Registration Number
NCT05053659
Locations
🇺🇸

Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

First Posted Date
2021-08-10
Last Posted Date
2024-08-22
Lead Sponsor
Juan P. Alderuccio, MD
Target Recruit Count
100
Registration Number
NCT04998669
Locations
🇺🇸

Allegheny Health Network, Pittsburgh, Pennsylvania, United States

🇺🇸

Florida Cancer Specialists and Research Institute, Fort Myers, Florida, United States

🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

and more 2 locations

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)

First Posted Date
2021-07-23
Last Posted Date
2022-03-29
Lead Sponsor
ADC Therapeutics S.A.
Registration Number
NCT04974996
Locations
🇺🇸

University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy